We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Pregnancy Tests Evaluated During Early Gravidity

By LabMedica International staff writers
Posted on 22 Apr 2014
Print article
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).
The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.

In a hospital setting, failure to detect pregnancy can lead to major consequences such as administration of medications that cause birth defects, fetal radiation exposure, or failure to diagnose ectopic pregnancy, which is the leading cause of first-trimester pregnancy-related maternal death.

Scientists at Washington University School of Medicine (St. Louis, MO, USA) tested a wide range of purified hCG and hCGβcf concentrations, which were mixed and tested on two POC devices. By use of those results, a screening method was defined and nine additional POC devices were evaluated. Two solutions containing 500 pmol/L (171 IU/L) intact hCG without hCGβcf and 500 pmol/L intact hCG with 500,000 pmol/L hCGβcf were used to screen all POC devices.

Varying concentrations of intact hCG and hCGβcf were combined in an hCG-negative urine matrix. Each solution was tested in duplicate by use of the SP hCG Combo Rapid Test (Cardinal Health; Dublin, OH, USA) and the OSOM hCG Combo Test (OSOM; Lexington, MA, USA). This screening method was then used to evaluate the performance of nine additional qualitative hCG POC devices. Visible differences in device performance were evident, resulting in the classification of the devices into three distinct groups: best performance, moderate performance, and poor performance.

The two best-performing devices were the Beckman Coulter Icon 20 (Brea, CA, USA) and the Alere hCG Combo (Waltham, MA, USA). The Icon 20 was the only device to exhibit an increased signal when hCGβcf was added to intact hCG. The Alere device was very modestly affected by the addition of hCGβcf. Two other tests present an unacceptable risk of false-negative results to patients after 5–7 weeks of pregnancy and the accuracy of the remaining seven tests was moderately affected by hCG beta core fragment.

Ann M. Gronowski, PhD, the senior author of the study said, “There are three important take home messages here. One, physicians, nurses, and other healthcare professionals need to be educated that this is a problem. Two, manufacturers need to make the possibility of false negatives clearly visible in their package inserts and work to develop better tests. And three, in centers where quantitative blood hCG testing is available, this should be the preferred pregnancy test. Blood testing is not subject to this effect because hCG beta core fragment is not present in serum.” The study was published in the April 2014 issue of the journal Clinical Chemistry.

Related Links:

Washington University School of Medicine 
Cardinal Health
Beckman Coulter



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.